In advanced-stage NSCLC patients, the response rates to these ICIs partly correlate with the level of PD-L1 expression, and patients with a high PD-L1 tumour proportion score (TPS) have shown greater response to ICIs versus patients who have a low TPS. Here, CD274 is linked to neoplasm.